Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Lamotrigine vs ATZUMI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.
Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.
Bipolar I disorder (maintenance treatment),Partial-onset seizures (adjunctive therapy),Primary generalized tonic-clonic seizures (adjunctive therapy),Lennox-Gastaut syndrome (seizures),Off-label: neuropathic pain, trigeminal neuralgia, schizophrenia augmentation
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults with PD-L1 expression ≥50%, with no EGFR or ALK genomic aberrations,First-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide,First-line treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic aberrations, in combination with bevacizumab, paclitaxel, and carboplatin,First-line treatment of metastatic squamous NSCLC in combination with paclitaxel and carboplatin,Treatment of locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy, or in cisplatin-ineligible patients with PD-L1 expression,Treatment of metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (d MMR) after prior fluoropyrimidine, oxaliplatin, and irinotecan therapy,Off-label uses: Various solid tumors with PD-L1 expression or MSI-H/d MMR
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.
1.2 g intravenously every 12 hours over 10-12 hours.
25.4 h (range 24-31 h, prolonged to 59 h with valproate)
Terminal elimination half-life is 12-15 hours in patients with normal renal function (Cr Cl >90 m L/min), allowing once-daily dosing. Renal impairment prolongs half-life (up to 30 hours in Cr Cl 30-50 m L/min).
Primarily metabolized by UDP-glucuronosyltransferases (UGT1A4, UGT2B7). Minimal involvement of CYP450 enzymes. Autoinduction of its own metabolism with chronic use.
Metabolized via catabolic pathways into small peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Renal (94% as metabolites, 10% unchanged; 2% fecal)
Approximately 70% of the dose is excreted renally as unchanged drug; 20% is eliminated via biliary/fecal routes as metabolites, with <5% as unchanged drug in feces.
55% (binds to albumin)
95% bound to albumin and alpha-1-acid glycoprotein; binding is saturable at high concentrations.
1.2 L/kg (distribution into tissues, including brain)
2.5-3.5 L/kg, indicating extensive extravascular distribution (e.g., tissues, erythrocytes).
Oral: 98% (immediate-release); ~90% (extended-release)
Oral: 70-80% (first-pass metabolism reduces bioavailability; food increases absorption by 15%).
e GFR <30 m L/min/1.73 m²: use with caution; no specific dose adjustment recommended. e GFR <10 m L/min: reduce dose by 50% and monitor.
Cr Cl 30-60 m L/min: 1.2 g every 18 hours; Cr Cl 10-29 m L/min: 1.2 g every 24 hours; Cr Cl <10 m L/min: 1.2 g loading dose then 0.6 g every 24 hours.
Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
2-12 years: 0.15 mg/kg/day once daily for 2 weeks, then 0.3 mg/kg/day once daily for 2 weeks, then increase by 0.3 mg/kg/day every 1-2 weeks. Maintenance: 1-5 mg/kg/day divided twice daily. Maximum: 400 mg/day.
Not approved for pediatric patients under 18 years.
Lower initial doses (25 mg every other day) and slower titration due to increased sensitivity and slower clearance; monitor for adverse effects.
No specific dose adjustment required; monitor renal function.
Life-threatening rashes, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), especially in pediatric patients and with rapid dose escalation.
None.
Risk of serious rash (SJS/TEN); hemophagocytic lymphohistiocytosis (HLH); aseptic meningitis; multiorgan hypersensitivity reactions; suicidal thoughts and behavior; blood dyscrasias; cardiac conduction abnormalities; increased seizure frequency with abrupt withdrawal.
Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin adverse reactions,Infusion-related reactions,Embryofetal toxicity,Increased risk of severe or fatal infection,Use caution in patients with autoimmune disease or organ transplant
Hypersensitivity to lamotrigine or any component of the formulation.
Severe hypersensitivity to atzumi or any excipients,Active severe autoimmune disease requiring systemic immunosuppression (relative),Pregnancy (embryofetal toxicity)
No significant food interactions. Grapefruit has no effect. Alcohol may increase CNS depression and dizziness; limit or avoid.
Avoid alcohol consumption during therapy and for 48 hours after last dose due to risk of disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions known.
First trimester exposure increases risk of oral clefts (cleft lip/palate) (absolute risk ~0.3-0.9% vs 0.2% background). Second/third trimester: risk of neural tube defects, cardiac malformations, and developmental delay. Higher doses (>300 mg/day) and polytherapy increase risk. Folate supplementation recommended.
Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avoid unless benefit outweighs risk.
Lamotrigine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6. Infant serum concentrations can reach 25-50% of maternal levels. Risk of rash, apnea, drowsiness; benefits likely outweigh risks in most cases. Monitor infant for adverse effects.
No data on excretion in human milk; M/P ratio unknown. Caution advised; use only if clearly needed.
Clearance increases by 50-330% during pregnancy, particularly in second and third trimesters. Dose may need to be increased (up to 2-3 times pre-pregnancy dose) to maintain therapeutic levels. Postpartum clearance returns to baseline within 1-2 weeks, requiring dose reduction to avoid toxicity.
No established dosing adjustments; pharmacokinetic changes in pregnancy may alter exposure. Monitor therapeutic response and adjust dose empirically based on clinical efficacy and toxicity.
Titrate slowly to minimize risk of Stevens-Johnson syndrome; start 25 mg/day for weeks 1–2, then 50 mg/day for weeks 3–4. Drug interactions: valproate doubles lamotrigine half-life and increases SJS risk; estrogen-containing contraceptives reduce lamotrigine levels by ~50%. Therapeutic serum level: 2.5–15 mcg/m L. Monitor for rash, especially in first 8 weeks.
ATZUMI (aztreonam) is a monobactam antibiotic with activity against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. It is often used in patients with severe beta-lactam allergies (e.g., anaphylaxis to penicillins) due to minimal cross-reactivity. Monitor renal function (creatinine clearance) as dose adjustment is required in renal impairment. For cystic fibrosis patients, higher doses or continuous infusion may be considered. Administer over 20-60 minutes to reduce infusion-related phlebitis. Note: Inhaled aztreonam lysine (not ATZUMI) is used for chronic pulmonary infections in cystic fibrosis.
Report any rash, hives, or blisters immediately; may be sign of serious skin reaction.,Do not stop taking abruptly; taper under doctor's guidance to avoid rebound seizures.,Take missed dose as soon as remembered unless close to next dose; do not double.,Oral contraceptives and hormone therapy can reduce lamotrigine effectiveness; discuss with doctor.,Avoid driving or operating machinery until effects are known; may cause dizziness or blurred vision.
Take this medication exactly as prescribed; do not skip doses or stop early unless instructed.,Report any signs of allergic reaction (rash, hives, itching, difficulty breathing, swelling of face/tongue) immediately.,Infusion site reactions (redness, swelling, pain) are common; notify healthcare provider if severe.,This drug may cause diarrhea, especially if prolonged; contact your doctor if watery or bloody stools occur.,Avoid alcohol while on this medication to reduce risk of disulfiram-like reaction (nausea, vomiting, headache).,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Complete full course even if you feel better to prevent antibiotic resistance.
"Telithromycin is a potent inhibitor of CYP3A4, while lamotrigine is primarily metabolized by UGT1A4 and not significantly by CYP3A4. However, telithromycin may also inhibit UGT1A4, leading to reduced lamotrigine clearance and increased risk of lamotrigine toxicity, including severe rash (Stevens-Johnson syndrome) and central nervous system depression. Concurrent use may require lamotrigine dose adjustment to avoid adverse effects."
"Concomitant use of Lormetazepam, a benzodiazepine that enhances GABAergic inhibition, and Lamotrigine, a sodium channel blocker and glutamate release inhibitor, may result in additive central nervous system depression and an increased risk of sedation, dizziness, and psychomotor impairment. The interaction is primarily pharmacodynamic, as both drugs have CNS depressant effects, potentially leading to excessive drowsiness and impaired coordination. Clinical outcomes may include increased fall risk, cognitive dysfunction, and compromised ability to perform tasks requiring alertness."
"Concurrent use of paliperidone and lamotrigine may increase the risk of central nervous system depression and synergistic adverse effects, including sedation, dizziness, and impaired cognitive function. Paliperidone, an atypical antipsychotic, and lamotrigine, an anticonvulsant, both modulate neurotransmitter systems, potentially leading to additive pharmacodynamic effects. Clinically, this can result in increased sedation, confusion, and an elevated risk of falls or accidents, particularly in elderly patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Lamotrigine vs ATZUMI, answered by our medical review team.
Lamotrigine is a Anticonvulsant that works by Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.. ATZUMI is a Benzodiazepine Anticonvulsant that works by Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Lamotrigine and ATZUMI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Lamotrigine is: Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.. The standard adult dose of ATZUMI is: 1.2 g intravenously every 12 hours over 10-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Lamotrigine and ATZUMI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Lamotrigine is classified as Category A/B. First trimester exposure increases risk of oral clefts (cleft lip/palate) (absolute risk ~0.3-0.9% vs 0.2% background). Second/third trimester: risk of neural tube defects, cardiac. ATZUMI is classified as Category C. Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.